Antimicrobial use in outpatient Hemodialysis units

Infection Control and Hospital Epidemiology

Volumn 34, Issue 4, 2013, Pages 349-357

  Snyder, Graham M ^a   Patel, Priti R ^b   Kallen, Alexander J ^b   Strom, James A ^c   Tucker, J Kevin ^d   D'Agata, Erika M C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM; CEFAZOLIN; CEPHALOSPORIN; DAPTOMYCIN; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

AGED; ANTIBIOTIC PROPHYLAXIS; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; CHARLSON COMORBIDITY INDEX; DRUG USE; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; PREVALENCE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SCORING SYSTEM;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; BOSTON; DRUG UTILIZATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INAPPROPRIATE PRESCRIBING; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POISSON DISTRIBUTION; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 84874922710     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/669869     Document Type: Article

References (35)

1. U.S. Renal Data System. USRDS 2009 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009.
2. Li Y, Friedman JY, O'Neal BF, et al. Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients. Clin J Am Soc Nephrol 2009;4(2):428-434.
3. Engemann JJ, Friedman JY, Reed SD, et al. Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. Infect Control Hosp Epidemiol 2005;26(6):534-539.
4. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum-/3-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006;50(4):1257-1262.
5. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006;42(suppl 2):S82-S89.
6. Centers for Disease Control and Prevention. Invasive methicil- lin-resistant Staphylococcus aureus infections among dialysis patients-United States, 2005. MMWR Morb Mortal Wkly Rep 2007;56(9): 197-199.
7. Snyder GM, D'Agata EM. Novel antimicrobial-resistant bacteria among patients requiring chronic hemodialysis. Curr Opin Ne- phrol Hypertens 2012;21(2):211-215.
8. Pop-Vicas A, Strom J, Stanley K, DAgata EM. Multidrug- resistant gram-negative bacteria among patients who require chronic hemodialysis. Clin J Am Soc Nephrol 2008;3(3):752-758.
9. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum /3-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001;32(8):1162-1171.
10. Dellit TH, Owens RC, McGowan JE, Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44(2): 159-177.
11. Klevens RM, Edwards JR, Andrus ML, Peterson KD, Dudeck MA, Horan TC. Dialysis Surveillance Report: National Health- care Safety Network (NHSN)-data summary for 2006. Semin Dial 2008;21(1):24-28.
12. George A, Tokars JI, Clutterbuck EJ, Bamford KB, Pusey C, Holmes AH. Reducing dialysis associated bacteraemia, and recommendations for surveillance in the United Kingdom: prospective study. BMJ 2006;332:1435.
13. Green K, Schulman G, Haas DW, Schaffner W, DAgata EM. Vancomycin prescribing practices in hospitalized chronic he- modialysis patients. Am J Kidney Dis 2000;35(1):64-68.
14. Zvonar R, Natarajan S, Edwards C, Roth V. Assessment of van- comycin use in chronic haemodialysis patients: room for im- provement. Nephrol Dial Transplant 2008;23(11):3690-3695.
15. Centers for Disease Control and Prevention. Central line- associated bloodstream infection (CLABSI) event. 2012; http:// www.cdc.gov/nhsn/TOC_PSC Manual.html. Accessed May 8, 2012.
16. Vascular Access 2006 Working Group. Clinical practice guide- lines for vascular access.Am J Kidney Dis 2006;48 (suppl 1):S 176- S273.
17. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005;40(5):643-654.
18. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneu- monia in adults. Clin Infect Dis 2007;44(suppl 2):S27-S72.
19. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41(10):1373-1406.
20. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995;44(RR-12): 1-13.
21. High KP, Bradley SF, Gravenstein S, et al. Clinical practice guide- line for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48(2): 149-171.
22. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and man- agement of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt) 2010;11(1):79-109.
23. Anderson DJ, Sexton DJ. Overview of control measures to pre- vent surgical site infection. In: Harris A, ed. UpToDate, http:// www.uptodate.com/contents/overview-of-control-measures-to- prevent-surgical-site-infection#H1. Published December 2012.
24. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005;111(23): e394-e434.
25. Centers for Disease Control and Prevention. NHSN Dialysis Event Protocol. 2012; http://www.cdc.gov/nhsn/psc_da_de.html. Accessed July 10, 2012.
26. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52(5):e103-e120.
27. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2010;50(5):625-663.
28. Mackowiak PA, Wasserman SS, Levine MM. A critical appraisal of 98.6°F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. JAMA 1992; 268(12): 1578-1580.
29. Dellinger EP, Gross PA, Barrett TL, et al. Quality standard for antimicrobial prophylaxis in surgical procedures. Infectious Diseases Society of America. Clin Infect Dis 1994;18(3):422-427.
30. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40(5):373-383.
31. Beddhu S, Zeidel ML, Saul M, et al. The effects of comorbid conditions on the outcomes of patients undergoing peritoneal dialysis. Am J Med 2002;112(9):696-701.
32. Schweizer ML, Furuno JP, Harris AD, et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methi- cillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis 2011;11:279.
33. Stryjewski ME, Szczech LA, Benjamin DK, Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007;44(2): 190-196.
34. Salman L, Asif A. Antibiotic prophylaxis: is it needed for dialysis access procedures? Semin Dial 2009;22(3):297-299.
35. Lu PL, Tsai JC, Chiu YW, et al. Methicillin-resistant Staphylo- coccus aureus carriage, infection and transmission in dialysis patients, healthcare workers and their family members. Nephrol Dial Transplant 2008;23(5):1659-1665.